Figure 5. Blocking PRMT5 attenuates lung cancer invasion and metastasis. (A–D) The ASTC-a-1 cells were treated with GSK591 or Vehicle, and the EMT markers (β-catenin, Vimentin, Slug, and E-cadherin) were determined by immunofluorescence. Representative pictures were shown (n=3, each group). Scale Bar=50μm. (E–H) The ASTC-a-1 cells were infected with lentivirus containing scramble-shRNA or PRMT5-shRNA1, and the EMT markers (β-catenin, Vimentin, Slug, and E-cadherin) were determined by immunofluorescence. Representative pictures were shown (n=3, each group). Scale Bar=50μm. (I) The ASTC-a-1 cells were infected with lentivirus containing scramble-shRNA, PRMT5-shRNA1, or PRMT5-shRNA2. The expression levels of EMT markers (β-catenin, Vimentin, and Slug) and PRMT5 knockdown efficiency were detected by Western blotting (n=3). (J) The ASTC-a-1 cells were treated with GSK591, and the expression levels of EMT markers (β-catenin, Vimentin, and Slug) were detected by Western blotting (n=3). (K) The ASTC-a-1 cells were treated with GSK591 or Vehicle or infected with lentivirus containing scramble-shRNA, PRMT5-shRNA1, or PRMT5-shRNA2. The PRMT5 enzyme activity was detected by Western blotting (n=3) using the SDMA antibody.